MedGenome has introduced OncoTrack MRD, a personalized blood test designed to track residual cancer cells in solid tumors that traditional scans might miss.
- MedGenome launches OncoTrack MRD for monitoring residual disease in solid tumors.
- The test uses circulating tumor DNA (ctDNA) to detect microscopic cancer cells.
- It complements traditional imaging like PET and CT scans.
- Targeted at cancers such as breast, lung, and pancreatic cancer.
In a significant advancement for oncology in India, genomics leader MedGenome has launched OncoTrack MRD. This tumor-informed molecular residual disease (MRD) test is specifically designed to monitor patients who have completed treatment for solid tumors, aiming to detect microscopic cancer cells that may still be lurking in the body.
For many cancer survivors, the greatest fear is recurrence. While conventional imaging such as PET scans, CT scans, and MRI are essential for visualizing tumor size and location, they have a fundamental limitation: a lesion must reach a certain biological mass before it becomes visible. OncoTrack MRD operates at a molecular level, asking not if a tumor can be seen, but if molecular evidence of that specific patient's cancer exists in the bloodstream.
The Science of Molecular Fingerprinting
Unlike generic blood tests, OncoTrack is 'tumor-informed.' This means the process begins by analyzing the patient's original tumor tissue to identify 50–100 specific mutations. This creates a personalized molecular "fingerprint." Subsequent blood tests then use ultra-deep sequencing to scan for this exact fingerprint using circulating tumor DNA (ctDNA).
Why This Matters
BozokMedia analysis shows that India faces a burgeoning cancer burden, with WHO-IARC reporting millions of cases annually. The ability to detect a rising molecular signal before a recurrence becomes clinically obvious through imaging could fundamentally shift cancer follow-up from reactive to proactive management, allowing for much earlier medical intervention.
OncoTrack MRD testing offers clinicians a powerful tool to identify patients who may need closer surveillance or earlier intervention.
It is important to distinguish this from multi-cancer early detection (MCED) screening. While screening aims to find cancer in healthy individuals, OncoTrack is a prognostic tool used after a diagnosis has already been made and treatment has been administered. It is intended to complement, rather than replace, existing clinical assessments.
| Feature | Traditional Imaging (PET/CT) | OncoTrack MRD Test |
|---|---|---|
| Detection Level | Macro (Visible Lesions) | Molecular (ctDNA) |
| Primary Use | Locating & Sizing Tumors | Detecting Residual Disease |
| Requirement | Physical Mass | Genetic Mutations |
Frequently Asked Questions
1. Is this a replacement for regular scans?
No, MedGenome emphasizes that this test is intended to complement imaging, providing an extra layer of molecular insight.
2. What is the cost of the test?
The baseline test is expected to cost around Rs 40,000, with subsequent monitoring tests costing approximately Rs 20,000.
